Literature DB >> 18499348

Nicotine abstinence-induced cerebral blood flow changes by genotype.

Ze Wang1, Riju Ray, Myles Faith, Kathy Tang, E Paul Wileyto, John A Detre, Caryn Lerman.   

Abstract

This study explored whether functional genetic variants previously associated with nicotine dependence are associated with regional cerebral blood flow (rCBF) changes during nicotine abstinence (compared to satiety; smoking as usual). Thirteen smokers participating in a prior arterial spin labeled (ASL) perfusion MRI study were scanned on two occasions (after >12h abstinence vs. satiety), and were genotyped for variants in the dopamine D2 receptor (DRD2-141 Ins/DelC; DRD2 C957T); a dopamine metabolizing enzyme (COMT val(158) met), and the mu opioid receptor (OPRM1 A118G). Significantly greater CBF increases were found in regions previously linked with cigarette cravings among carriers of the DelC variant of DRD2-141 and among the COMT val/val group. Smokers with TT genotypes for the DRD2 C957T exhibited less change in rCBF in abstinence relative to satiety, compared to those with CC or CT genotypes. Finally, smokers with OPRM1 AA genotypes showed significant increases in CBF in regions associated previously with cigarette cravings. While preliminary, these results suggest a neural mechanism through which these genetic variants may be linked with nicotine dependence, and provide further support for increased biological vulnerability in these subgroups of smokers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499348      PMCID: PMC2474789          DOI: 10.1016/j.neulet.2008.04.084

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  26 in total

1.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.

Authors:  Joseph A Maldjian; Paul J Laurienti; Robert A Kraft; Jonathan H Burdette
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

2.  The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.

Authors:  C Lerman; E P Wileyto; F Patterson; M Rukstalis; J Audrain-McGovern; S Restine; P G Shields; V Kaufmann; D Redden; N Benowitz; W H Berrettini
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

3.  A unified statistical approach for determining significant signals in images of cerebral activation.

Authors:  K J Worsley; S Marrett; P Neelin; A C Vandal; K J Friston; A C Evans
Journal:  Hum Brain Mapp       Date:  1996       Impact factor: 5.038

4.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

Review 5.  Genetics and smoking cessation improving outcomes in smokers at risk.

Authors:  Caryn E Lerman; Robert A Schnoll; Marcus R Munafò
Journal:  Am J Prev Med       Date:  2007-12       Impact factor: 5.043

6.  Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx.

Authors:  Ze Wang; Geoffrey K Aguirre; Hengyi Rao; Jiongjiong Wang; María A Fernández-Seara; Anna R Childress; John A Detre
Journal:  Magn Reson Imaging       Date:  2007-09-10       Impact factor: 2.546

7.  DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues.

Authors:  F Joseph McClernon; Kent E Hutchison; Jed E Rose; Rachel V Kozink
Journal:  Psychopharmacology (Berl)       Date:  2007-07-05       Impact factor: 4.530

8.  C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo.

Authors:  M Hirvonen; A Laakso; K Någren; J O Rinne; T Pohjalainen; J Hietala
Journal:  Mol Psychiatry       Date:  2004-12       Impact factor: 15.992

9.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.

Authors:  Jubao Duan; Mark S Wainwright; Josep M Comeron; Naruya Saitou; Alan R Sanders; Joel Gelernter; Pablo V Gejman
Journal:  Hum Mol Genet       Date:  2003-02-01       Impact factor: 6.150

10.  Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects.

Authors:  Laura M Parkes; Waqar Rashid; Declan T Chard; Paul S Tofts
Journal:  Magn Reson Med       Date:  2004-04       Impact factor: 4.668

View more
  19 in total

Review 1.  Pharmacogenetics of OPRM1.

Authors:  Richard C Crist; Wade H Berrettini
Journal:  Pharmacol Biochem Behav       Date:  2013-11-05       Impact factor: 3.533

Review 2.  Neuroimaging, genetics and the treatment of nicotine addiction.

Authors:  Riju Ray; James Loughead; Ze Wang; John Detre; Edward Yang; Ruben Gur; Caryn Lerman
Journal:  Behav Brain Res       Date:  2008-06-05       Impact factor: 3.332

3.  Brain Marker Links Stress and Nicotine Abstinence.

Authors:  Cheyenne Allenby; Mary Falcone; Rebecca L Ashare; Wen Cao; Leah Bernardo; E Paul Wileyto; Jens Pruessner; James Loughead; Caryn Lerman
Journal:  Nicotine Tob Res       Date:  2020-05-26       Impact factor: 4.244

Review 4.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

Review 5.  Use of magnetic resonance imaging in pharmacogenomics.

Authors:  Roberto Viviani; Marie-Louise Lehmann; Julia C Stingl
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

6.  Organic cation transporter variation and response to smoking cessation therapies.

Authors:  Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Martha Michel; Denise Nishita; David V Conti; Christopher K Edlund; Pui-Yan Kwok; Jennifer B McClure; Richard B Kim; Sharon M Hall; Rachel F Tyndale; Timothy B Baker; Neal L Benowitz; Gary E Swan
Journal:  Nicotine Tob Res       Date:  2014-08-20       Impact factor: 4.244

Review 7.  Applications of arterial spin labeled MRI in the brain.

Authors:  John A Detre; Hengyi Rao; Danny J J Wang; Yu Fen Chen; Ze Wang
Journal:  J Magn Reson Imaging       Date:  2012-01-13       Impact factor: 4.813

8.  Examining the effects of initial smoking abstinence on response to smoking-related stimuli and response inhibition in a human laboratory model.

Authors:  Matthew P Bradstreet; Stephen T Higgins; F Joseph McClernon; Rachel V Kozink; Joan M Skelly; Yukiko Washio; Alexa A Lopez; Marie A Parry
Journal:  Psychopharmacology (Berl)       Date:  2013-12-15       Impact factor: 4.530

Review 9.  Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment.

Authors:  Sarah W Yip; Marc N Potenza
Journal:  Clin Psychol Rev       Date:  2016-11-09

Review 10.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.